Cargando…
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
The 6th Cardiovascular Outcome Trial (CVOT) Summit “Cardiovascular and Renal Outcomes 2020” was the first to be held virtually on October 29–30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010779/ https://www.ncbi.nlm.nih.gov/pubmed/33789663 http://dx.doi.org/10.1186/s12933-021-01254-1 |
_version_ | 1783673124749836288 |
---|---|
author | Schnell, Oliver Cos, Xavier Cosentino, Francesco Forst, Thomas Giorgino, Francesco Heersprink, Hiddo J. L. Kosiborod, Mikhail Wanner, Christoph Standl, Eberhard |
author_facet | Schnell, Oliver Cos, Xavier Cosentino, Francesco Forst, Thomas Giorgino, Francesco Heersprink, Hiddo J. L. Kosiborod, Mikhail Wanner, Christoph Standl, Eberhard |
author_sort | Schnell, Oliver |
collection | PubMed |
description | The 6th Cardiovascular Outcome Trial (CVOT) Summit “Cardiovascular and Renal Outcomes 2020” was the first to be held virtually on October 29–30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed. The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18–19, 2021 (http://www.cvot.org). |
format | Online Article Text |
id | pubmed-8010779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80107792021-03-31 Report from the CVOT Summit 2020: new cardiovascular and renal outcomes Schnell, Oliver Cos, Xavier Cosentino, Francesco Forst, Thomas Giorgino, Francesco Heersprink, Hiddo J. L. Kosiborod, Mikhail Wanner, Christoph Standl, Eberhard Cardiovasc Diabetol Commentary The 6th Cardiovascular Outcome Trial (CVOT) Summit “Cardiovascular and Renal Outcomes 2020” was the first to be held virtually on October 29–30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed. The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18–19, 2021 (http://www.cvot.org). BioMed Central 2021-03-31 /pmc/articles/PMC8010779/ /pubmed/33789663 http://dx.doi.org/10.1186/s12933-021-01254-1 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary Schnell, Oliver Cos, Xavier Cosentino, Francesco Forst, Thomas Giorgino, Francesco Heersprink, Hiddo J. L. Kosiborod, Mikhail Wanner, Christoph Standl, Eberhard Report from the CVOT Summit 2020: new cardiovascular and renal outcomes |
title | Report from the CVOT Summit 2020: new cardiovascular and renal outcomes |
title_full | Report from the CVOT Summit 2020: new cardiovascular and renal outcomes |
title_fullStr | Report from the CVOT Summit 2020: new cardiovascular and renal outcomes |
title_full_unstemmed | Report from the CVOT Summit 2020: new cardiovascular and renal outcomes |
title_short | Report from the CVOT Summit 2020: new cardiovascular and renal outcomes |
title_sort | report from the cvot summit 2020: new cardiovascular and renal outcomes |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010779/ https://www.ncbi.nlm.nih.gov/pubmed/33789663 http://dx.doi.org/10.1186/s12933-021-01254-1 |
work_keys_str_mv | AT schnelloliver reportfromthecvotsummit2020newcardiovascularandrenaloutcomes AT cosxavier reportfromthecvotsummit2020newcardiovascularandrenaloutcomes AT cosentinofrancesco reportfromthecvotsummit2020newcardiovascularandrenaloutcomes AT forstthomas reportfromthecvotsummit2020newcardiovascularandrenaloutcomes AT giorginofrancesco reportfromthecvotsummit2020newcardiovascularandrenaloutcomes AT heersprinkhiddojl reportfromthecvotsummit2020newcardiovascularandrenaloutcomes AT kosiborodmikhail reportfromthecvotsummit2020newcardiovascularandrenaloutcomes AT wannerchristoph reportfromthecvotsummit2020newcardiovascularandrenaloutcomes AT standleberhard reportfromthecvotsummit2020newcardiovascularandrenaloutcomes |